

# The Oncologist's Guide to Synoptic Reporting: A Primer

Ekkehard Hewer

Institute of Pathology, University of Bern, Bern, Switzerland

Short Title: The Oncologist's Guide to Synoptic Reporting

Correspondence to:

Ekkehard Hewer

Institute of Pathology

University of Bern

Murtenstrasse 31

3008 Bern, Switzerland

Tel: +41 31 632 3211

Fax: +41 31 632 9938

E-mail: [ekkehard.hewer@pathology.unibe.ch](mailto:ekkehard.hewer@pathology.unibe.ch)

ORCID: 0000-0002-9128-0364

Keywords: Synoptic reporting – Structured reporting – International Collaboration on Cancer Reporting

1 **Abstract**

2 Synoptic reporting in tumour pathology is defined by (1) completeness in terms of data  
3 elements as well as (2) a specific, laboratory value-like format. Adoption of synoptic reporting  
4 leads to more complete reporting of essential parameters, improved standardization of  
5 diagnostic criteria and terminology as well as easier retrieval of information. It is therefore  
6 associated with a high degree of satisfaction among end users including surgeons and  
7 oncologists and contributes to improvement of clinical care. Furthermore, synoptic reporting  
8 is an important step towards higher levels of data capture, which facilitate data exchange and  
9 analysis for quality assurance, cancer epidemiology and clinical and basic research.

10 Increased interest in and adoption of synoptic reporting on a global level is stimulated by the  
11 International Collaboration on Cancer Reporting (ICCR) which publishes freely available,  
12 evidence-based datasets for reporting an increasing number of different cancer types.

13 These developments pave a path for increased future application of synoptic reporting  
14 across the entire field of oncologic medicine, where it will likely deploy similar benefits as in  
15 pathology. Given that synoptic reporting can be considered the most precise means for  
16 reporting of medical findings available, it may be predicted to be critical for the promises of  
17 precision medicine to become real.

18

## 19 **The need for complete and standardized reporting in Oncologic Pathology**

20 Oncologic pathology reports have a key role in diagnostic work-up, therapeutic management  
21 and post-therapeutic follow-up of every cancer patient. Given the multidisciplinary of current  
22 oncologic management, it is natural that various specialists rely of different types of  
23 information. These specialists include, but are not limited to medical and radiation  
24 oncologists, surgeons, diagnostic and interventional radiologists, nuclear medicine  
25 physicians and pathologists themselves. Additional stakeholders include cancer registries,  
26 clinical researchers, biobanking experts and quality managers. Furthermore, it is  
27 increasingly acknowledged that patients demand access to their reports – which in turn may  
28 influence how the information therein should be presented [1].

29 It would require almost supranatural abilities from a pathologist to keep all these  
30 stakeholders in mind when signing out reports and to address their needs – or even to know  
31 what all of these actually are in the context of each specific cancer type, histological subtype,  
32 type of specimen, tumour stage, eligibility for (neo-) adjuvant therapies, etc.

33 An additional level of complexity arises from the fact that is insufficient for a pathologist just  
34 to describe what they see under the microscope: Cut-offs for a biomarker to be reported as  
35 positive or negative may vary depending on the context. For different organs there may be  
36 subtle differences in the diagnostic criteria for vascular invasion or in the definition of  
37 involvement of surgical margins. Furthermore, these classifications change over time – or  
38 there may be competing classifications or definitions at a given time point. Therefore, even a  
39 report given by the hypothetical near-supranatural pathologist mentioned above might lead to  
40 confusion, when it remains unclear what the underlying classifications and criteria were.

## 41 **Synoptic reporting**

42 Pathologists have long acknowledged these challenges and recognized *Synoptic Reporting*  
43 (derived from ancient Greek “syn-opsis” – overview) as a means to address them[2]. It was  
44 realized early on that the decision process which parameters to include was critical and non-  
45 trivial [3, 4]. Among a number of institutions, which have published protocols for synoptic  
46 reports in the past, two main players have emerged in the past years. The College of  
47 American Pathologists (CAP) publishes the most comprehensive set of synoptic cancer  
48 protocols as of now [5]. Their use has been mandatory for CAP accredited laboratories which  
49 has been a major driver for synoptic reporting in the United States and internationally. More  
50 recently, an International Collaboration on Cancer Reporting (ICCR), sponsored by a variety  
51 of international pathology organizations, has been launched [6-8]. ICCR has started to  
52 publish sets of protocols for various cancer types with the aim to cover the major cancer  
53 types. Both CAP and ICCR follow a strictly defined process for dataset development and  
54 consultation to ensure a broad consensus, expertise and reflection of the best evidence  
55 available.

## 56 **Format of Synoptic Reporting**

57 Initially, the term “synoptic” simply meant to indicate any structured format other than running  
58 text, usually with different data elements mentioned in separate lines [2]. CAP defines SR  
59 more narrowly [5], in that synoptic reports must not only encompass a set of required data  
60 elements (RDE), but also adhere to a “paired format”, where the designation of each RDE is  
61 followed by a “response”. In essence, this is the way how clinical laboratory values are  
62 reported (Table 1). Separate RDE must be displayed in separate lines.

63 Apart from this, CAP accepts a broad variety of possible formats and text markups. Of note,  
64 the range of acceptable formats includes low-technology implementations such as filling in  
65 and printing the protocols in Microsoft Word format or even photocopying protocols in order  
66 to fill them in manually. Similarly, the International Collaboration on Cancer Reporting (ICCR)  
67 provides its protocols in portable document format (PDF) which can be printed and filled in  
68 manually. CAP specifically permits to present the RDE in any order and to include additional  
69 data elements at each institution's and/or pathologist's discretion[5]. Furthermore, additional  
70 narrative sections are acceptable.

### 71 **Terminology: safety issues and uniformity**

72 Neither CAP, nor ICCR have published detailed information on how specific wordings are  
73 chosen for data elements or responses. A number of recurrent themes emerges, however,  
74 when comparing the various protocols and their development over time: Generally, there is a  
75 strong tendency toward uniformity within and across protocols. Positive findings, for example,  
76 are usually reported as "present" rather than "yes" or "positive". Similarly, CAP protocols  
77 uniformly use the term "extranodal extension" rather than "extracapsular extension".

78 Negative findings are usually reported as "not identified" rather than "absent" along the line of  
79 the statement that "absence of evidence is not evidence of absence" and acknowledging the  
80 insight that in medicine the latter can rarely be provided. Of note, biomarkers for which the  
81 positive result reflects the normal situation are reported e.g. as "Intact nuclear expression"  
82 vs. "Loss of nuclear expression" rather than "positive"/"negative".

83 Different responses to one data element are usually designed not to differ only by a single  
84 word, which might be accidentally omitted and thereby invert the intended meaning, e.g. "not  
85 identified" rather than "not present". Also, there is a tendency towards some degree of  
86 redundancy, such as in the case of grading, i.e. "G2, moderately differentiated" rather than  
87 just "G2".

88 All of the above conventions aim at minimization of risks associated with misinterpretations of  
89 reports. Such considerations should be kept in mind while implementing synoptic protocols  
90 locally or translating them to different languages.

### 91 **Advantages of Synoptic Reporting:**

92 A major advantage of synoptic over narrative reporting is an increase in completeness of  
93 data elements, as demonstrated by a number of studies across various cancer types,  
94 including – but not limited to – colorectal, lung, breast and prostate cancer as well as  
95 cutaneous malignant melanoma [9-16]. One study of cutaneous malignant melanoma found  
96 completeness of reports to increase not only in non-specialised, but also in a specialized  
97 setting [11]. A meta-analysis on the effects of synoptic reporting [16] found an increase in  
98 completeness in 13 out of 14 studies. This increase in completeness is critical, as lack of  
99 core data elements may affect quality of cancer care [10, 17]. Of note, the actual rates of  
100 completeness achieved by synoptic reporting varies significantly between studies, indicating  
101 that the characteristics of implementation may be an important factor. Furthermore, synoptic  
102 reporting may contribute to increased awareness of quality indicators and thereby improve  
103 quality of pathologic evaluation. Interestingly, the meta-analysis mentioned above [16] found  
104 an increase in numbers of lymph nodes obtained from colorectal cancer resections as well as  
105 a higher percentage of specimens reaching the minimum of 12 lymph nodes upon  
106 introduction of synoptic reporting.

107 Overall, synoptic reporting is associated with a high degree of satisfaction in pathologists,  
108 surgeons and oncologists [18, 19]. This satisfaction seems to be associated with perceived  
109 completeness of reports for the purpose of clinical decision making as well as ease of finding  
110 relevant information [18] (Figure 1).

### 111 **Limitations of Synoptic Reporting**

112 The overall high level of satisfaction with synoptic reporting notwithstanding, a similarly  
113 recurrent theme across various studies is that pathologists need more time to complete  
114 synoptic as compared to narrative reports [18]. Generally, however, the increment in time  
115 was moderate and considered acceptable when considering the benefits of synoptic  
116 reporting.

117 An additional issue may be the length of reports. Most of the CAP protocol files extend over  
118 several pages, while the more compact format adopted by ICCR may be challenging to  
119 render within an existing laboratory information system. In part, increased length of reports is  
120 an intrinsic consequence of completeness in terms of RDE as well as of the synoptic format  
121 itself. Nevertheless, overly long reports can be avoided by a number of means: First, many  
122 RDE are conditional, i.e. they may be mandatory only in a subset of cases (e.g. nuclear  
123 grading does not apply to chromophobe renal cell carcinoma). In that case, it is acceptable to  
124 omit the pertinent line completely, rather than reporting the RDE as “not applicable”. Second,  
125 most CAP and ICCR protocols contain a number of optional data elements, which may or  
126 may not be reported at each pathologist’s or institution’s discretion. It may be prudent in this  
127 context, to refrain from including “everything”, but rather to keep readability of reports in  
128 mind. Along the same line, some hesitation may be advisable with regard to including  
129 additional data elements on a local basis.

130 Finally, synoptic protocols may not fit well very specific circumstances, such as two different  
131 histologic tumour types (e.g. carcinoma and lymphoma) occurring in the same resection  
132 specimens. Usually, however, such issues can be addressed in a satisfactory manner, and  
133 the possibility to include free text provides sufficient flexibility.

### 134 **How to read synoptic reports**

135 In most instances, synoptic reports should be sufficiently self-explanatory in order to be well  
136 understandable to physicians with at least some understanding of the respective medical  
137 field. In particular, preferences of individual pathologists with respect to wording should be  
138 less of an issue than with narrative reports. Furthermore, as cancer protocols are  
139 continuously updated, synoptic reports will usually contain the information required for patient  
140 management in current terminology and with sufficient granularity. When very specific  
141 information is required, the notes accompanying each cancer or biomarker protocol may be a  
142 useful resource. CAP protocols contain a “Notes” section, which gives very detailed  
143 information on diagnostic criteria, cut-offs, grading schemes, etc. ICCR protocols are  
144 available in bookmarked and hyperlinked versions containing similar information. The  
145 respective documents are freely available on the CAP and ICCR websites. Ideally, a synoptic  
146 report should contain information, to which version of which protocol it refers. This is of  
147 particular relevance with regard to future users, given that classifications change over time.

### 148 **Synoptic reporting on the path towards higher levels of data capture**

149 As discussed by Ellis and Srigley [20], synoptic reporting has a middle position regarding the  
150 degree to which data is structured and is classified as Level 3 in a 6-tiered system:

- 151 • Level 1: Narrative report (no defined content)
- 152 • Level 2: Narrative report with standardized content (e.g. by using a checklist for  
153 dictation)
- 154 • Level 3: Synoptic report – adds a specific format, but not necessarily any underlying  
155 software implementation
- 156 • Level 4: Synoptic report with electronic reporting tools
- 157 • Level 5: Standardised structured report with underlying database structure
- 158 • Level 6: Standardised structured report with binding terminology in order to facilitate  
159 data exchange

160 According to Ellis and Srigley, implementation of Level 3, primarily benefits immediate clinical  
161 needs, while higher levels of data capture are necessary for synoptic reporting to unfold its  
162 full potential for pathologists and secondary users. An underlying database structure will  
163 allow pathologists to easily monitor statistical distribution of findings and thereby identify  
164 potential deviations from expected frequencies, which in turn might point towards issues on a  
165 technical or interpretational level.

166 Ultimately, linking synoptic reports and databases with a uniform terminology, such as  
167 SNOMED-CT, will allow third parties including biobanks and cancer registries to access large  
168 datasets with unprecedented granularity.

169 Nevertheless, synoptic reporting according to Level 3 in the Ellison/Srigley classification has  
170 an important role within the path towards higher levels of data capture: It serves one  
171 particular purpose, i.e. clinicians' needs, already very well. Furthermore, it can be  
172 implemented relatively more easily, fast and without major financial implications. Finally, it  
173 may be a very significant step on a psychological level, as it trains users to adhere to a  
174 standardized format and terminology and fosters precision in reporting.

### 175 **Synoptic reporting in oncology beyond pathology**

176 While the historic origin and widest application of synoptic reporting are in oncologic  
177 pathology, its concepts are spreading non-neoplastic pathology [21, 22] as well as oncologic  
178 specialities other than pathology. Main areas of application of synoptic reporting include  
179 radiology [23-27] and operative reports in surgery [28-33]. While the overall number of  
180 studies addressing the effects of synoptic reporting is considerably lower than in pathology,  
181 they tend to show similar outcomes; completeness of reports increases with the use of  
182 synoptic reporting, while at the same time the amount of non-essential information is reduced  
183 [34-36]. A web-based synoptic reporting tool for thyroid surgery was found to achieve 100%  
184 completeness of essential prognostic factors while completeness varied between 3% and  
185 >95% for various parameters in descriptive operative reports [37]. Of note, initiatives for  
186 synoptic reporting in radiology or oncologic surgery are mostly driven by single academic  
187 centres. In contrast to pathology, so far there is only a limited role of national or international

188 professional or scientific societies. One exception is the American Thyroid Association, which  
189 has issued a statement regarding essential elements of perioperative information in relation  
190 to thyroid surgery and endorsed use of synoptic operative reports [31].

## 191 **Perspective**

192 Over more than a quarter of a century, the concept of synoptic reporting in pathology has  
193 matured from local initiatives [2] to international standardization with defined processes for  
194 design and maintenance of evidence-based reporting templates which are coordinated with  
195 the World Health Organization Classification of Tumours [6, 38, 39]. Data is increasingly  
196 structured and linked to ontologies such as SNOMED-CT and LOINC [40], facilitating  
197 unprecedented levels of integration with the potential to revolutionize their use with regard to  
198 clinical care, quality assurance, as well as clinical and basic research [41].

199 This development paves a path for future widespread applications of synoptic reporting (and  
200 higher levels of data capture) in other fields in oncology. Not only do the forces, which have  
201 driven this development in pathology – the need for complete, accurate and standardized  
202 information – act on all oncologic specialties, but also can synoptic reporting be predicted to  
203 be a major part of the respective solutions. Experience from pathology shows that high  
204 quality, evidence-based and timely consensus forms for reporting and their endorsement by  
205 national and international professional and scientific societies are critically important  
206 facilitators for widespread application of synoptic reporting.

207 For precision medicine not to remain an empty promise, precision has to be the *modus*  
208 *operandi* in the entire practice of oncologic medicine and synoptic reporting is the most  
209 precise type of communication available to us.

## 210 **Statement of Ethics**

211 The author has no ethical conflicts to disclose.

212

## 213 **Disclosure Statement**

214 The author has no conflicts of interest to declare.

## References

- 1 Lee CI, Langlotz CP, Elmore JG: Implications of Direct Patient Online Access to Radiology Reports Through Patient Web Portals. *J Am Coll Radiol* 2016;13:1608-1614.
- 2 Markel SF, Hirsch SD: Synoptic surgical pathology reporting. *Hum Pathol* 1991;22:807-810.
- 3 Dworak O: Synoptic surgical pathology reporting. *Hum Pathol* 1992;23:85-86.
- 4 Chamberlain DW, Wenckebach GF, Alexander F, Fraser RS, Kolin A, Newman T: Pathological examination and the reporting of lung cancer specimens. *Clin Lung Cancer* 2000;1:261-268.
- 5 College of American Pathologists website,
- 6 International Collaboration on Cancer Reporting (ICCR) website
  
- 7 Bullock MJ, Beitler JJ, Carlson DL, Fonseca I, Hunt JL, Katabi N, Sloan P, Taylor SM, Williams MD, Thompson LDR: Data Set for the Reporting of Nodal Excisions and Neck Dissection Specimens for Head and Neck Tumors: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting (ICCR). *Arch Pathol Lab Med* 2018
- 8 Nicholson AG, Detterbeck F, Marx A, Roden AC, Marchevsky AM, Mukai K, Chen G, Marino M, den Bakker MA, Yang WI, Judge M, Hirschowitz L: Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). *Histopathology* 2017;70:522-538.
- 9 Messenger DE, McLeod RS, Kirsch R: What impact has the introduction of a synoptic report for rectal cancer had on reporting outcomes for specialist gastrointestinal and nongastrointestinal pathologists? *Arch Pathol Lab Med* 2011;135:1471-1475.
- 10 Haydu LE, Holt PE, Karim RZ, Madronio CM, Thompson JF, Armstrong BK, Scolyer RA: Quality of histopathological reporting on melanoma and influence of use of a synoptic template. *Histopathology* 2010;56:768-774.
- 11 Karim RZ, van den Berg KS, Colman MH, McCarthy SW, Thompson JF, Scolyer RA: The advantage of using a synoptic pathology report format for cutaneous melanoma. *Histopathology* 2008;52:130-138.
- 12 Aumann K, Amann D, Gump V, Hauschke D, Kayser G, May AM, Wetterauer U, Werner M: Template-based synoptic reports improve the quality of pathology reports of prostatectomy specimens. *Histopathology* 2012;60:634-644.
- 13 Aumann K, Kayser G, Amann D, Bronsert P, Hauschke D, Palade E, Passlick B, Werner M: The format type has impact on the quality of pathology reports of oncological lung resection specimens. *Lung Cancer* 2013;81:382-387.
- 14 Aumann K, Niermann K, Asberger J, Wellner U, Bronsert P, Erbes T, Hauschke D, Stickeler E, Gitsch G, Kayser G, Werner M: Structured reporting ensures complete content and quick detection of essential data in pathology reports of oncological breast resection specimens. *Breast Cancer Res Treat* 2016;156:495-500.
- 15 Maley A, Patrawala S, Stoff B: Compliance with the College of American Pathologists Protocol for Melanoma in Synoptic and Non-Synoptic reports: A cross-sectional study. *J Am Acad Dermatol* 2016;74:179-181.



- 16 Sluijter CE, van Lonkhuijzen LR, van Slooten HJ, Nagtegaal ID, Overbeek LI: The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review. *Virchows Arch* 2016;468:639-649.
- 17 Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I: Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. *Eur J Cancer* 2011;47:57-64.
- 18 Lankshear S, Srigley J, McGowan T, Yurcan M, Sawka C: Standardized synoptic cancer pathology reports - so what and who cares? A population-based satisfaction survey of 970 pathologists, surgeons, and oncologists. *Arch Pathol Lab Med* 2013;137:1599-1602.
- 19 Hammond EH, Flinner RL: Clinically relevant breast cancer reporting: using process measures to improve anatomic pathology reporting. *Arch Pathol Lab Med* 1997;121:1171-1175.
- 20 Ellis DW: Surgical pathology reporting at the crossroads: beyond synoptic reporting. *Pathology* 2011;43:404-409.
- 21 Benton SJ, Lafreniere AJ, Gynspan D, Bainbridge SA: A synoptic framework and future directions for placental pathology reporting. *Placenta* 2019;77:46-57.
- 22 Edwards PC: Is it time to extend synoptic reporting to include potentially preneoplastic oral epithelial and lichenoid lesions? *Oral Surg Oral Med Oral Pathol Oral Radiol* 2017;124:105-106.
- 23 Panicek DM, Hricak H: Recommendations for the Initial Cancer Staging MRI Report. *J Magn Reson Imaging* 2019
- 24 Patel A, Rockall A, Guthrie A, Gleeson F, Worthy S, Grubnic S, Burling D, Allen C, Padhani A, Carey B, Cavanagh P, Peake MD, Brown G: Can the completeness of radiological cancer staging reports be improved using proforma reporting? A prospective multicentre non-blinded interventional study across 21 centres in the UK. *BMJ Open* 2018;8:e018499.
- 25 Kennedy ED, Milot L, Fruitman M, Al-Sukhni E, Heine G, Schmocker S, Brown G, McLeod RS: Development and implementation of a synoptic MRI report for preoperative staging of rectal cancer on a population-based level. *Dis Colon Rectum* 2014;57:700-708.
- 26 Spiegler G, Leon-Carlyle M, Schmocker S, Fruitman M, Milot L, Gagliardi AR, Smith AJ, McLeod RS, Kennedy ED: Development of a synoptic MRI report for primary rectal cancer. *Implement Sci* 2009;4:79.
- 27 Dhillon RS, King JA, Goldschlager T, Wang YY: Synoptic reporting of pituitary magnetic resonance imaging. *ANZ J Surg* 2018;88:460-463.
- 28 Ehrlich PF: Reply to: Synoptic operative reports for quality improvement in pediatric cancer care: Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: A report from the Children's Oncology Group. *Pediatr Blood Cancer* 2018;65:e27277.
- 29 Cundy TP, Kirby CP, Kirby ML: Synoptic operative reports for quality improvement in pediatric cancer care. *Pediatr Blood Cancer* 2018;65:e27238.
- 30 Brower ST, Katz M, Pisters P, Merchant N, Weber S, Posner M: Electronic synoptic operative reporting for pancreatic resection. *J Am Coll Surg* 2011;212:425-426; author reply 426.

- 31 Carty SE, Doherty GM, Inabnet WB, 3rd, Pasiaka JL, Randolph GW, Shaha AR, Terris DJ, Tufano RP, Tuttle RM, Surgical Affairs Committee Of The American Thyroid A: American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. *Thyroid* 2012;22:395-399.
- 32 Badruddoja M: Electronic synoptic operation report. *J Am Coll Surg* 2011;212:271-272.
- 33 Temple WJ, Chin-Lenn L, Mack LA, Cancer Surgery A: Evaluating population-based breast cancer surgical practice in real time with a web-based synoptic operative reporting system. *Am J Surg* 2014;207:693-696; discussion 696-697.
- 34 Eng JL, Baliski CR, McGahan C, Cai E: Completeness of breast cancer operative reports in a community care setting. *Breast* 2017;35:91-97.
- 35 King S, Dimech M, Johnstone S: Structured pathology reporting improves the macroscopic assessment of rectal tumour resection specimens. *Pathology* 2016;48:349-352.
- 36 Maniar RL, Hochman DJ, Wirtzfeld DA, McKay AM, Yaffe CS, Yip B, Silverman R, Park J: Documentation of quality of care data for colon cancer surgery: comparison of synoptic and dictated operative reports. *Ann Surg Oncol* 2014;21:3592-3597.
- 37 Chambers AJ, Pasiaka JL, Temple WJ: Improvement in the accuracy of reporting key prognostic and anatomic findings during thyroidectomy by using a novel Web-based synoptic operative reporting system. *Surgery* 2009;146:1090-1098.
- 38 Ellis DW, Srigley J: Does standardised structured reporting contribute to quality in diagnostic pathology? The importance of evidence-based datasets. *Virchows Arch* 2016;468:51-59.
- 39 Comperat E, Babjuk M, Algaba F, Amin M, Brimo F, Grignon D, Hansel D, Hes O, Malavaud B, Reuter V, van der Kwast T: SIU-ICUD on bladder cancer: pathology. *World J Urol* 2019;37:41-50.
- 40 Campbell WS, Karlsson D, Vreeman DJ, Lazenby AJ, Talmon GA, Campbell JR: A computable pathology report for precision medicine: extending an observables ontology unifying SNOMED CT and LOINC. *J Am Med Inform Assoc* 2017
- 41 Banz Y, Berezowska S, de Leval L, Rubbia-Brandt L, Tolnay M, Moch H, Perren A, Hewer E: Advancing synoptic cancer reports beyond English: the University of Bern/PathoLink approach. *Virchows Arch* 2018;473:655-656.

**Table**

Narrative	Synoptic
<p>Upon incubation with the patient's serum, immunofluorescence microscopy shows staining of neutrophils in a perinuclear pattern. This is still visible when the serum is diluted 1:320, but not at 1:640 dilution</p>	<p>ANCA: positive (p-ANCA); Titer 1:320</p>
<p><i>The synoptic format of data element, paired with a response recapitulates the way clinical laboratory values are reported. This example of immunofluorescence illustrates that it would appear unusual to physicians to receive such test results in narrative text, even though there may be a similar type of analysis underlying the test result.</i></p>	
<p>... with lymph node metastases detected in 3 out of 12 lymph nodes, largest diameter 1.2 cm, without evidence of extracapsular extension ...</p>	<p>Number of lymph nodes submitted: 12 Number of lymph nodes involved: 3 Largest diameter of lymph node metastasis: 1.2cm Extranodal extension: not identified</p>
<p><i>Example of typical elements from a surgical pathology report. Most readers would likely find it more easy to extract a particular piece of information from the synoptic as compared to the narrative report.</i></p>	
<p>15% of tumour cells are positive for Mum-1.</p>	<p>Mum-1 (immunostaining): negative</p>
<p>15% of tumour cells are positive for p53.</p>	<p>p53 (immunostaining): wildtype pattern</p>
<p>15% of tumour cells are positive for Ki-67.</p>	<p>Ki-67 proliferation index: 15%</p>
<p><i>In particular for biomarkers, specific criteria may have to be applied for interpretation of a given finding. 15% of stained tumour cell nuclei would not qualify for Mum-1 expression in the context of the Hans Algorithm for determining cell of origin in diffuse large B cell lymphoma. Depending on how the immunostaining is set up, 15% of nuclear p53 staining would likely indicate wildtype TP53. In contrast, for Ki-67 the percentage of positive nuclei is reported (with specific recommendations on how many nuclei to count for some tumour types).</i></p>	

Table 1. Examples of information that might be found in laboratory or pathology reports in narrative and synoptic format.

## Figure

### Lung, upper lobe, right, lobectomy:

Single focus (greatest tumor diameter 3.2 cm) of an invasive adenocarcinoma with acinar (80%) and solid (20%) growth patterns, localized in the upper lobe, with visceral pleura invasion, without lymphovascular invasion. No adjacent structures present. All margins uninvolved by carcinoma (including bronchial, vascular and parenchymal margins). Minimal distance of invasive carcinoma from margin is 1.8cm (from the bronchial margin). No known history of presurgical therapy. Mild emphysematous alterations of non-neoplastic pulmonary tissue.

### Synoptic Report (Lung, Resection)

Procedure laterality, tumor site: lobectomy, right, upper lobe  
Tumor size: 3.2cm  
Tumor focality: Single tumor  
Histologic type: Invasive adenocarcinoma, acinar predominant (80%)  
Other subtypes present: solid (20%)  
Visceral Pleura Invasion: present  
Lymphovascular invasion: not identified  
Direct invasion of adjacent structures: No adjacent structures present  
Margins: All margins uninvolved by carcinoma  
Distance of carcinoma from closest margin: 1.8cm (Bronchial Margin)  
Margins examined: Bronchial, Vascular, Parenchymal  
Treatment effect: No known presurgical therapy

Figure 1. Color-coded representation of data elements (according to the College of American Pathologists template for lung cancer) in narrative (top) and synoptic (bottom) formats. Even when complete in terms of required data elements, narrative reports tend to be shorter than synoptic reports. Finding a particular piece of information, however, is easier with the synoptic format. As in this example, narrative reports tend to include more non-essential data of little clinical relevance (mild emphysematous change) than synoptic reports, while essential data elements are often incomplete.